Hofseth BioCare ASA reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported sales was NOK 49.62 million compared to NOK 29.79 million a year ago. Revenue was NOK 49.89 million compared to NOK 30.22 million a year ago. Net loss was NOK 22.72 million compared to NOK 35.07 million a year ago. Basic loss per share from continuing operations was NOK 0.06 compared to NOK 0.09 a year ago. Diluted loss per share from continuing operations was NOK 0.06 compared to NOK 0.09 a year ago.
For the nine months, sales was NOK 144.93 million compared to NOK 85.28 million a year ago. Revenue was NOK 171.09 million compared to NOK 86.84 million a year ago. Net loss was NOK 54.79 million compared to NOK 99.17 million a year ago. Basic loss per share from continuing operations was NOK 0.14 compared to NOK 0.27 a year ago. Diluted loss per share from continuing operations was NOK 0.14 compared to NOK 0.27 a year ago.